PL3043816T3 - Przeciwciała anty-b7-h1 do leczenia nowotworów - Google Patents
Przeciwciała anty-b7-h1 do leczenia nowotworówInfo
- Publication number
- PL3043816T3 PL3043816T3 PL14766962T PL14766962T PL3043816T3 PL 3043816 T3 PL3043816 T3 PL 3043816T3 PL 14766962 T PL14766962 T PL 14766962T PL 14766962 T PL14766962 T PL 14766962T PL 3043816 T3 PL3043816 T3 PL 3043816T3
- Authority
- PL
- Poland
- Prior art keywords
- antibodies
- treating tumors
- tumors
- treating
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361876509P | 2013-09-11 | 2013-09-11 | |
| US201461971212P | 2014-03-27 | 2014-03-27 | |
| US201461978401P | 2014-04-11 | 2014-04-11 | |
| US201462003349P | 2014-05-27 | 2014-05-27 | |
| PCT/EP2014/069425 WO2015036499A1 (en) | 2013-09-11 | 2014-09-11 | Anti-b7-h1 antibodies for treating tumors |
| EP14766962.6A EP3043816B1 (en) | 2013-09-11 | 2014-09-11 | Anti-b7-h1 antibodies for treating tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3043816T3 true PL3043816T3 (pl) | 2020-03-31 |
Family
ID=51570487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14766962T PL3043816T3 (pl) | 2013-09-11 | 2014-09-11 | Przeciwciała anty-b7-h1 do leczenia nowotworów |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10336823B2 (pl) |
| EP (2) | EP3043816B1 (pl) |
| JP (5) | JP6550053B2 (pl) |
| KR (4) | KR102661249B1 (pl) |
| CN (2) | CN105873606B (pl) |
| AU (3) | AU2014320343B2 (pl) |
| BR (1) | BR112016005303A2 (pl) |
| CA (1) | CA2923499A1 (pl) |
| DK (1) | DK3043816T3 (pl) |
| ES (1) | ES2749744T3 (pl) |
| HU (1) | HUE046674T2 (pl) |
| IL (5) | IL321966A (pl) |
| MX (1) | MX370818B (pl) |
| NZ (2) | NZ757060A (pl) |
| PL (1) | PL3043816T3 (pl) |
| RU (1) | RU2701327C2 (pl) |
| SA (1) | SA516370713B1 (pl) |
| TW (1) | TWI643633B (pl) |
| WO (1) | WO2015036499A1 (pl) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150131269A (ko) | 2013-03-15 | 2015-11-24 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| BR112016005303A2 (pt) * | 2013-09-11 | 2017-09-12 | Medimmune Ltd | anticorpos anti-b7-h1 para tratamento de tumores |
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| CA2936962C (en) | 2014-03-14 | 2024-03-05 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| BR112016027881A2 (pt) * | 2014-05-29 | 2017-10-24 | Medimmune Ltd | antagonistas de pdl-1 e pd-1 para o tratamento de cânceres negativos para o hpv |
| EP3149042B1 (en) | 2014-05-29 | 2019-08-28 | Spring Bioscience Corporation | Pd-l1 antibodies and uses thereof |
| BR112017000497B1 (pt) | 2014-07-11 | 2023-12-26 | Ventana Medical Systems, Inc | Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1 |
| WO2016034718A1 (en) * | 2014-09-05 | 2016-03-10 | Medimmune Limited | Methods for identifying patients responsive to anti-pd-l1 antibody therapy using markers (cxcl9, krt8.trim29, and ifngamma) |
| CA2960824A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of alk inhibitors |
| CA2964367C (en) | 2014-10-14 | 2024-01-30 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| WO2016124558A1 (en) | 2015-02-03 | 2016-08-11 | Ventana Medical Systems, Inc. | Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1) |
| SG10201810615VA (en) | 2015-02-26 | 2019-01-30 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for the treatment of cancer |
| JP6826055B2 (ja) | 2015-03-13 | 2021-02-03 | サイトメックス セラピューティクス インコーポレイテッド | 抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| CA2983067A1 (en) * | 2015-04-23 | 2016-10-27 | Medimmune Limited | Combination therapy for non-small cell lung cancer positive for egfr mutation |
| RS61152B2 (sr) * | 2015-05-12 | 2024-06-28 | Hoffmann La Roche | Terapeutski i dijagnostički postupci za lečenje raka |
| EP3307777A4 (en) | 2015-06-11 | 2019-02-13 | Wuxi Biologics (Shanghai) Co. Ltd. | NOVEL ANTI-PD-L1 ANTIBODIES |
| US10869924B2 (en) | 2015-06-16 | 2020-12-22 | Merck Patent Gmbh | PD-L1 antagonist combination treatments |
| US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| WO2017019896A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| CN106939047B (zh) | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| WO2017176565A1 (en) | 2016-04-07 | 2017-10-12 | Eli Lilly And Company | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor |
| US20190144545A1 (en) * | 2016-05-26 | 2019-05-16 | Merck Patent Gmbh | PD-1/PD-L1 Inhibitors for Cancer Treatment |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| WO2017220989A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| JP6910653B2 (ja) * | 2016-07-01 | 2021-07-28 | 国立大学法人東北大学 | 免疫チェックポイント阻害薬使用における免疫関連副作用の予測方法 |
| IL265762B2 (en) | 2016-10-06 | 2024-04-01 | Merck Patent Gmbh | Dosing regimen of avelumab for the treatment of cancer |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| JP7250764B2 (ja) | 2017-08-18 | 2023-04-03 | コセラ バイオサイエンス， インコーポレイテッド | Ｔｇ０２の多形形態 |
| CN111971059A (zh) * | 2018-01-31 | 2020-11-20 | 细胞基因公司 | 使用过继细胞疗法和检查点抑制剂的组合疗法 |
| EP3768713A2 (en) | 2018-03-22 | 2021-01-27 | Keires AG | Antagonistic pd-1, pd-l1 and lag-3 binding proteins |
| JP7574198B2 (ja) | 2019-01-18 | 2024-10-28 | ドラセン ファーマシューティカルズ インコーポレイテッド | Ｄｏｎプロドラッグおよび免疫チェックポイント阻害剤による組み合わせ治療法 |
| CA3127388A1 (en) * | 2019-01-25 | 2020-07-30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Combined pharmaceutical composition for treating tumor |
| MA55516A (fr) | 2019-03-26 | 2022-02-09 | Univ Michigan Regents | Agents de dégradation, à petites molécules, de stat3 |
| EP3947403A1 (en) | 2019-03-29 | 2022-02-09 | The Regents Of The University Of Michigan | Stat3 protein degraders |
| AU2020291936A1 (en) | 2019-06-12 | 2022-02-03 | Vanderbilt University | Dibenzylamines as amino acid transport inhibitors |
| CN114222729A (zh) | 2019-06-12 | 2022-03-22 | 范德比尔特大学 | 氨基酸转运抑制剂及其用途 |
| CN114173794A (zh) * | 2019-06-25 | 2022-03-11 | 希望之城 | Pdl1阳性nk细胞癌症治疗 |
| US12485174B2 (en) | 2019-06-27 | 2025-12-02 | The George Washington University, A Congressionally Chartered Not-For-Profit Corporation | HDAC6-activated macrophages, compositions, and uses thereof |
| WO2021011713A1 (en) | 2019-07-16 | 2021-01-21 | The Regents Of The University Of Michigan | Imidazopyrimidines as eed inhibitors and the use thereof |
| AU2020336381A1 (en) | 2019-08-27 | 2022-03-03 | The Regents Of The University Of Michigan | Cereblon E3 ligase inhibitors |
| WO2021055756A1 (en) | 2019-09-19 | 2021-03-25 | The Regents Of The University Of Michigan | Spirocyclic androgen receptor protein degraders |
| EP4034568A4 (en) * | 2019-09-25 | 2024-02-14 | Wuxi Biologics Ireland Limited | Novel anti-pd-l1 antibodies |
| WO2021195481A1 (en) | 2020-03-26 | 2021-09-30 | The Regents Of The University Of Michigan | Small molecule stat protein degraders |
| WO2022011204A1 (en) | 2020-07-10 | 2022-01-13 | The Regents Of The University Of Michigan | Small molecule androgen receptor protein degraders |
| US20230233690A1 (en) | 2020-07-10 | 2023-07-27 | The Regents Of The University Of Michigan | Androgen receptor protein degraders |
| WO2022072820A1 (en) | 2020-10-02 | 2022-04-07 | Dracen Pharmaceuticals, Inc. | Lyophilized composition comprising (s)-isopropyl 2-((s)-2- acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5- oxohexanoate for subcutaneous administration and the use thereof |
| US20240166647A1 (en) | 2021-03-03 | 2024-05-23 | The Regents Of The University Of Michigan | Cereblon Ligands |
| US20240190874A1 (en) | 2021-03-03 | 2024-06-13 | The Regents Of The University Of Michigan | Small molecule degraders of androgen receptor |
| CA3213407A1 (en) * | 2021-03-26 | 2022-09-29 | Astrazeneca Ab | Combination treatments for melanoma |
| EP4658310A1 (en) | 2023-01-30 | 2025-12-10 | Kymab Limited | Antibodies |
| WO2025151487A2 (en) | 2024-01-08 | 2025-07-17 | Regents Of The University Of Michigan | Small-molecule inhibitors of adar1 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2192884C2 (ru) * | 2000-11-09 | 2002-11-20 | Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН | Вакцина для стимуляции противоопухолевого иммунитета |
| US7794710B2 (en) * | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
| US20100285039A1 (en) * | 2008-01-03 | 2010-11-11 | The Johns Hopkins University | B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells |
| KR101050829B1 (ko) * | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| CN101693562A (zh) * | 2009-10-21 | 2010-04-14 | 山东大学 | 一种聚合氯化铁-聚环氧氯丙烷-二甲胺复合混凝剂 |
| LT3279215T (lt) * | 2009-11-24 | 2020-04-10 | Medimmune Limited | Tiksliniai surišantys agentai prieš b7-h1 |
| LT2785375T (lt) * | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | Anti-pd-l1 antikūnai ir jų panaudojimas |
| WO2013173223A1 (en) * | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| BR112016005303A2 (pt) * | 2013-09-11 | 2017-09-12 | Medimmune Ltd | anticorpos anti-b7-h1 para tratamento de tumores |
| RS59134B1 (sr) * | 2014-05-13 | 2019-09-30 | Medimmune Ltd | Anti-b7-h1 i anti-ctla-4 antitela za tretman nesitnoćelijskog kancera pluća |
| US10092645B2 (en) * | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| WO2016034718A1 (en) * | 2014-09-05 | 2016-03-10 | Medimmune Limited | Methods for identifying patients responsive to anti-pd-l1 antibody therapy using markers (cxcl9, krt8.trim29, and ifngamma) |
| US20170320954A1 (en) * | 2014-11-17 | 2017-11-09 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| US20160347848A1 (en) * | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| AU2017257505B2 (en) * | 2016-04-25 | 2020-05-14 | Medimmune, Llc | Compositions comprising coformulation of anti-PD-L1 and Anti-CTLA-4 antibodies |
| MX2018013762A (es) * | 2016-05-13 | 2019-03-28 | Medimmune Llc | Polipeptidos de fusion de ligando de cumulo de diferenciacion 40 y fragmento cristalizable (cd40l-fc) y sus metodos de uso. |
-
2014
- 2014-09-11 BR BR112016005303A patent/BR112016005303A2/pt not_active Application Discontinuation
- 2014-09-11 MX MX2016002826A patent/MX370818B/es active IP Right Grant
- 2014-09-11 WO PCT/EP2014/069425 patent/WO2015036499A1/en not_active Ceased
- 2014-09-11 PL PL14766962T patent/PL3043816T3/pl unknown
- 2014-09-11 DK DK14766962.6T patent/DK3043816T3/da active
- 2014-09-11 KR KR1020227040760A patent/KR102661249B1/ko active Active
- 2014-09-11 JP JP2016542315A patent/JP6550053B2/ja active Active
- 2014-09-11 IL IL321966A patent/IL321966A/en unknown
- 2014-09-11 KR KR1020217037457A patent/KR20210143932A/ko not_active Ceased
- 2014-09-11 AU AU2014320343A patent/AU2014320343B2/en active Active
- 2014-09-11 EP EP14766962.6A patent/EP3043816B1/en active Active
- 2014-09-11 RU RU2016113341A patent/RU2701327C2/ru active
- 2014-09-11 CN CN201480049982.1A patent/CN105873606B/zh active Active
- 2014-09-11 KR KR1020167007277A patent/KR102329584B1/ko active Active
- 2014-09-11 NZ NZ757060A patent/NZ757060A/en unknown
- 2014-09-11 KR KR1020247013414A patent/KR20240056664A/ko not_active Ceased
- 2014-09-11 NZ NZ718821A patent/NZ718821A/en unknown
- 2014-09-11 CA CA2923499A patent/CA2923499A1/en active Pending
- 2014-09-11 ES ES14766962T patent/ES2749744T3/es active Active
- 2014-09-11 HU HUE14766962A patent/HUE046674T2/hu unknown
- 2014-09-11 US US15/021,161 patent/US10336823B2/en active Active
- 2014-09-11 CN CN202011433007.4A patent/CN112546217B/zh active Active
- 2014-09-11 TW TW103131437A patent/TWI643633B/zh active
- 2014-09-11 IL IL292193A patent/IL292193B2/en unknown
- 2014-09-11 EP EP19191552.9A patent/EP3656398A1/en active Pending
-
2016
- 2016-03-03 IL IL244422A patent/IL244422B/en active IP Right Grant
- 2016-03-10 SA SA516370713A patent/SA516370713B1/ar unknown
-
2019
- 2019-04-23 JP JP2019081639A patent/JP2019163269A/ja active Pending
- 2019-05-21 US US16/418,488 patent/US10829557B2/en active Active
-
2020
- 2020-05-05 IL IL274462A patent/IL274462B/en unknown
- 2020-08-27 AU AU2020223728A patent/AU2020223728B2/en active Active
- 2020-09-10 JP JP2020152079A patent/JP7119037B2/ja active Active
- 2020-10-16 US US17/072,756 patent/US11827706B2/en active Active
-
2022
- 2022-02-16 JP JP2022021883A patent/JP7342167B2/ja active Active
-
2023
- 2023-08-30 JP JP2023139429A patent/JP2023166474A/ja active Pending
-
2024
- 2024-05-29 IL IL313188A patent/IL313188B2/en unknown
- 2024-06-07 AU AU2024203898A patent/AU2024203898A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL313188B2 (en) | Anti-B7-H1 antibodies for tumor treatment | |
| IL269528A (en) | Anti- FCRH5 antibodies | |
| IL245196A0 (en) | Antibodies against cd38 for the treatment of human cancers | |
| SG11201603050TA (en) | Methods for treating cancers | |
| GB201322583D0 (en) | Antibodies | |
| IL244043A0 (en) | Antibodies | |
| GB201308658D0 (en) | Antibodies | |
| GB201315486D0 (en) | Antibodies | |
| IL281541A (en) | Specific anti-cd38 antibodies for treating human cancers | |
| IL245488A0 (en) | Anti- ccl17 antibodies | |
| GB201312226D0 (en) | Improved antibodies | |
| PL3016682T3 (pl) | Sposoby leczenia nowotworu | |
| ZA201504169B (en) | Anti-adam28 antibody for treating cancer | |
| GB201321531D0 (en) | Treatment for cancers | |
| GB201318283D0 (en) | Antibodies |